Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Trevena (TRVN) PT Lowered to $2 at Cantor Fitzgerald
-
Auxly Cannabis (XLY:CN) (CBWTF) PT Lowered to Cdn$0.21 at Cantor Fitzgerald
-
Cutera (CUTR) PT Raised to $85 at Cantor Fitzgerald as AviClear Could Change Acne Paradigm
-
Trulieve Cannabis Corp (TCNNF) PT Lowered to $59 at Cantor Fitzgerald
-
Clarus (CRXT) PT Lowered to $3 at Cantor Fitzgerald
-
Form 10-K Cantor Fitzgerald Income For: Dec 31
-
Ric Kayne and Affiliates Confirm Nomination of Two Highly Qualified Candidates for Election to Athira Pharma’s Board of Directors
-
Satellogic (SATL) Elects Tom Killalea to its Board of Directors
-
Satellogic Elects Tom Killalea to its Board of Directors
-
Cantor Fitzgerald Lowers PT to $5, Reiterates Overweight Rating on PAVmed (PAVM)
-
PAVmed Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results
-
Cantor Fitzgerald Starts Nerdy (NRDY) at Overweight
-
Capricor Therapeutics to Participate in the Cantor Fitzgerald Rare Orphan Disease Summit
-
Cantor Fitzgerald Reiterates Overweight Rating and $12 PT on Lucid Diagnostics (LUCD), "We Encourage Investors to Acquire LUCD Shares at Attractive Valuation"
-
Jushi Holding (JUSHF) PT Lowered to $3.05 at Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Overweight Rating on Fortress Biotech (FBIO), Sees Upward Earnings Revisions and Multiple Expansion
-
Cantor Fitzgerald Reiterates Overweight Rating on Arcutis Biotherapeutics (ARQT)
-
Lucid Diagnostics Inc (LUCD) Provides Business Update, Reports Prelim Q4
-
Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results
-
UPDATE: Trulieve Cannabis Corp (TCNNF) PT Lowered to $60 at Cantor Fitzgerald
-
Abeona Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
-
Abeona Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
-
UPDATE: HUTCHMED (China) (HCM) and Viatris (VTRS) Top Cantor Fitzgerald's List of Biggest Short Interest Increases, Heron (HRTX) and Omeros (OMER) Continue to Have Higher Short Floats
-
Anavex Life Sciences to Participate in the Cantor Virtual Rare Orphan Disease Summit
-
Arcturus Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
-
Cantor Fitzgerald Reiterates Overweight Rating on Graybug Vision (GRAY) with $4 PT, Believes Stock Deserves Greater Attention from Investors
-
Cantor Fitzgerald Reiterates ContraFect (CFRX) at Overweight with $15 PT, Expects Upwards Earnings Revisions
-
Cantor Fitzgerald Reiterates Aspira Women’s Health (AWH) at Overweight with $4 PT, Sees Shares as "Materially Undervalued"
-
DURECT Corporation To Present at the 2022 Cantor Fitzgerald Virtual Rare Orphan Disease Summit
-
Longboard Pharmaceuticals to Participate in Cantor Fitzgerald’s Virtual Rare Orphan Disease Summit
-
Exela Technologies (XELA) PT Lowered to $2 at Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Aytu Biosciences (AYTU) at Overweight, $11 PT, Sees it as Positive Development Potentially Extending ADHD Franchise Revenue Runway
-
Cantor Fitzgerald Reiterates Overweight Rating on Lucid Diagnostics Inc (LUCD), Sees Launch in Three New Areas as Favorable and as an Important Commercialization Milestone
-
Cantor Fitzgerald Reiterates Pfizer (PFE) at Overweight Rating with $75 PT on Phase 3 etrasimod Data
-
Exagen (XGN) PT Lowered to $19 at Cantor Fitzgerald on Weaker Guidance, but Analyst Maintained Overweight Rating and Positive Outlook, "Would Encourage Investors to Acquire Shares" at Current Valuatio
-
MariMed to Participate in April Investor Conferences
-
Chemomab Therapeutics to Participate in Cantor Fitzgerald Rare Orphan Disease Summit
-
Options mavens see stock rebound as chance to pick up downside protection
-
Lanvin Group, a Global Luxury Fashion Group, to Become Publicly Traded on the NYSE via Business Combination with Primavera Capital Acquisition Corporation
-
Applied Genetic Technologies (AGTC) Prices 7.5M Share Offering at $1.31/sh
-
AGTC Announces Pricing of Public Offering of Common Stock
-
AGTC Announces Pricing of Public Offering of Common Stock
-
Reigo Doubles Securitization to $200 Million in Residential Bridge Loans
-
Troika Media (TRKA) Completes Transformative Acquisition of Converge Direct LLC Adding Approximately $300 Million of Revenue and $21 Million of Net Income
-
Troika Media Group Completes Transformative Acquisition of Converge Direct LLC Adding Approximately $300 Million of Revenue and $21 Million of Net Income
-
Troika Media Group Completes Transformative Acquisition of Converge Direct LLC Adding Approximately $300 Million of Revenue and $21 Million of Net Income
-
Troika Media Group Completes Transformative Acquisition of Converge Direct LLC Adding Approximately $300 Million of Revenue and $21 Million of Net Income
-
Troika Media Group Completes Transformative Acquisition of Converge Direct LLC Adding Approximately $300 Million of Revenue and $21 Million of Net Income
-
Aytu BioPharma to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
-
Decibel Therapeutics to Participate in Upcoming Investor Conferences

